Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 495-500

  Van Hecken, Anne ^a,c   Depré, Marleen ^a   Verbesselt, René ^a   Wynants, Kathleen ^a   De Lepeleire, Inge ^d   Arnout, Jef ^b   Wong, Peggy H ^d   Freeman, Amanda ^d   Holland, Sherry ^d   Gertz, Barry ^d   De Schepper, Paul J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONTELUKAST; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG METABOLISM; ENANTIOMER; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LEUKOTRIENE ANTAGONISTS; MALE; PROTHROMBIN TIME; QUINOLINES; WARFARIN;

EID: 0032784566     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. 4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
2. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB: Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Int Med 1998;158:1213-1220.
3. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A: Montelukast for chronic asthma in 6- to 14-year old children. JAMA 1998;279:1181-1186.
4. 1 receptor antagonist, in human plasma and bile. Drug Metabolism and Disposition 1997;25:1282-1287.
5. Harder S, Thürmann P: Clinically important drug interactions with anticoagulants. Clin Pharmacokinet 1996;30:416-444.
6. Banfield C, Rowland M: Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma. J Pharm Sci 1983;73:921-924.
7. Hirsch J: Oral anticoagulant drugs. N Engl J Med 1991;324:1865-1875.
8. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, et al: Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996;13:445-448.
9. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, et al: Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Disp 1997;18:769-777.
10. Schall R, Müller O, Hündt HKL, Ritter W, Duursema L, Groenewoud G, Middle MV: No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 1995;35:306-313.
11. Rocci ML, Vlasses PH, Distlerath L, Gregg MH, Wheeler SC, Zing W, Bjornsson TD: Norfloxacin does not alter warfarin's disposition or anticoagulant effect. J Clin Pharmacol 1990;30:728-732.
12. Kong Ah-Ng T, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;35:1008-1015.
13. Suttle AB, Vargo DL, Wilkinson LA, Lasseter KC: Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men. Clin Pharm Ther 1997;61:186.